Immuneering Corporation Announces Grants of Inducement Awards

Immuneering Corporation Announces Grants of Inducement --> Accessibility: Skip TopNav Immuneering Corporation Announces Grants of Inducement Awards July 17, 2026 16:05 ET | Source: Immuneering Corporation Immuneering Corporation NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the “Start Date”). In connection with the commencement of Mr. Gengos’s employment, on July 16, 2026, Mr. Gengos was granted an option to purchase 650,000 shares of the Company’s Class A common stock (“Common Stock”) with a per share exercise price of $4.78, the closing trading price of the Common Stock on the Nasdaq Global Market on July 16, 2026 (the “Closing Price”). The stock option was granted pursuant to the Company’s 2025 Employment Inducement Award Plan (the “Inducement Plan”) and was approved by the Company’s Board of Directors (the “Board”). The stock option has a ten-year term and vests (subject to Mr. Gengos’s continued service to the Company through the applicable vesting dates) as follows: 8.33333% of the initial shares underlying the option shall vest on each of the first, second and third monthly anniversary of the Start Date; 1.6667% of the initial shares underlying the option shall vest on the fourth monthly anniversary of the Start Date and on each monthly anniversary thereafter until the one-year anniversary of the Start Date; 3.33333% of the initial shares underlying the option shall vest on each monthly anniversary following the one-year anniversary of the Start Date until the second anniversary of the Start Date; and 0.833333% of the of the initial shares underlying the option shall vest on each monthly anniversary following the second anniversary of the Start Date until the fourth anniversary of the Start Date, such that the stock option shall be fully vested and exercisable on the fourth anniversary of the Start Date. The stock option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules (the “Nasdaq Rules”) as an inducement material to Mr. Gengos entering into employment with the Company. Additionally, in connection with the commencement of employment of a non-executive employee, also on July 16, 2026, such employee was granted an option to purchase 32,400 shares of Common Stock with a per share exercise price equal to the Closing Price. The stock option was granted pursuant to the Inducement Plan and was approved by the Compensation Committee of the Board. The stock option has a ten-year term and vests (subject to the employee’s continued service to the Company through the applicable vesting dates) 25% on July 16, 2027 and the remaining 75% in substantially equal monthly installments over the three years thereafter, such that the stock option shall be fully vested and exercisable on July 16, 2030. The stock option was granted under the Nasdaq Rules as an inducement material to the employee entering into employment with the Company. About Immuneering Corporation Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com . Forward Looking Statements This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: Immuneering’s plans to develop, and the treatment potential of, its product candidates. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be mate